ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2013
Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas.
Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Claudin-18.2 in Gastric and Gastroesophageal Junction Adenocarcinoma: From Biology to Therapeutic Targeting: A Narrative Review.Targeted oncology · 2026Review
- Immunohistochemical profiling of ampullary carcinoma: Molecular subtypes, prognostic markers, and the role of Claudin-18.Virchows Archiv : an international journal of pathology · 2026Article
- Antibody-drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges.Cancer chemotherapy and pharmacology · 2026Review
- Claudins in ovarian cancer: emerging biomarkers and therapeutic targets.Tissue barriers · 2026Review
- Claudins in Cancer: A Current and Future Therapeutic Target.International journal of molecular sciences · 2024Review
- Restoration of fertility in nonablated recipient mice after spermatogonial stem cell transplantation.Stem cell reports · 2024Article
- The Expression of the Claudin Family of Proteins in Colorectal Cancer.Biomolecules · 2024Review
- Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases.Journal of hepatocellular carcinoma · 2024Review
- Review
- Article
- S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer.Cell death and differentiation · 2023Article
- Claudin and pancreatic cancer.Frontiers in oncology · 2023Review
- Claudin-4 localization in epithelial ovarian cancer.Heliyon · 2022Article
- Decrement of Transcriptome Level in Epithelial Tight Junction Claudin and Occludin as an Epithelial-Mesenchymal Transition Signature for Colorectal Cancer Biomarker : Colorectal Cancer Diagnostic Markers.Galen medical journal · 2022Article
- Effects of 1,2-Dimethylhydrazine on Barrier Properties of Rat Large Intestine and IPEC-J2 Cells.International journal of molecular sciences · 2021Article
- Article
- Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components.Molecular biology reports · 2021Article
- Claudin-1, A Double-Edged Sword in Cancer.International journal of molecular sciences · 2020Review
- Tight Junctions in Cell Proliferation.International journal of molecular sciences · 2019Review
- Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas.Histopathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tight junction proteins, including claudins, are often dysregulated during carcinogenesis and tumor progression. Moreover, the claudin expression pattern usually varies between different tumor entities. We aimed to investigate claudin expression profiles of primary and metastatic liver malignancies. We analyzed claudin-1, -2, -3, -4, and -7 expression by quantitative immunohistochemistry and real-time RT-PCR, respectively. Twenty hepatocellular carcinomas (HCCs) and liver metastases of 20 colorectal adenocarcinomas (CRLMs) and 15 pancreatic adenocarcinomas (PLMs) were studied together with paired surrounding non-tumorous liver samples and 5 normal liver samples. Strong claudin-3 and -7 immunohistochemical positivities were detected in CRLM samples, each with significantly stronger staining when compared with HCC and PLM groups. Claudin-1 protein was found highly expressed in CRLM, in contrast to lower expression in PLM and HCC. CRLMs and PLMs also were strongly positive for claudin-4, while being virtually undetectable in HCC. Claudin-2 showed strong positivity in non-tumorous liver tissue, whereas significantly weaker positivity was observed in all tumors. Differences in mRNA expression were mostly similar to those found by immunohistochemistry. In conclusion, HCC and both CRLM and PLM display distinct claudin expression profiles, which might provide better understanding of the pathobiology of these lesions and might be used for differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.